>...
数据说明

1. 本数据库涵盖了FDA官网所有公布的溶出数据,根据官网不定期更新。
2.本数据库提供药物名称、剂型、溶出介质、USP溶出方法等多字段检索。
3. 本数据库中的药物名称与药渡数据库中药物做了人工关联,支持药物中文名称、商品名以及各种药物别名检索。

关闭

FDA溶出 筛选 共1323条数据
更新日期:2018-11-28

  • 药物名称
  • 容积
  • 推荐采样时间
  • 剂型
    • Powder for suspension (Immediate Release)
    • Implant (Intravitreal)
    • Transdermal Patch
    • Intrauterine Device
    • Tablet (Buccal)
    • Tablet Orally Disintegrating)
    • Tablet (Effervescent)
    • Capsule
    • Vaginal Tablet
    • Suspension
    • Film (Oral)
    • Injectable (Extended Release)
    • Film (Buccal)
    • Capsule/Tablet/Capsule (Copackage)
    • Tablet (for Oral Suspension)
    • Tablet (Regular)
    • Tablet (Chewable dispersible)
    • Rectal Suppository
    • For Oral Suspension
    • Tablet (Delayed Release)
    • Film, Transdermal (Extended Release)
    • Transdermal
    • Granule
    • Powder for Oral Solution
    • Capsule (Delayed Release)
    • Gel (Topical)
    • Topical patch
    • Tablets
    • Lozenge (Mini)
    • Oral Suspension (Pediatric)
    • Tablet (Extended Release, Chewable)
    • Tablet (Orally Disintegrating)
    • Tablet (Combination)
    • Oral Supension
    • Powder for suspension (Extended Release)
    • Otic Suspension
    • Rectal Enema
    • Tablet (Copackage)
    • Capsules
    • OTC Tablet (Delayed Release)
    • Suspension/Drop
    • Oral Suspension
    • Tablet (Orally Disintegrating (ODT))
    • Capsule (Extended Release)
    • Film (Sublingual)
    • Tablet (Sublingual)
    • Suspension (Enteral)
    • Capsule (Sprinkle)
    • Tablet
    • Film, Transdermal
    • Tablet (Delayed Release), For Solution,
    • Vaginal Insert
    • Tablet (Chewable)
    • Capsule (Soft-Gelatin)
    • Injectable Suspension
    • Extended Release Oral Suspension
    • Delayed Release Granules for Oral Suspension
    • Tablet (Delayed Release, Orally Disintegrating)
    • Capsule (Micronized)
    • Tablet (Vaginal)
    • Chewing Gum
    • Suspension (Extended Release)
    • Capsule (Delayed Release Pellets)
    • Granules for Oral suspension
    • Suppository (Vaginal)
    • Pellet Implant
    • Capsule (Delayed Release)
    • ER Tablets
    • Powder for oral
    • Intramuscular Suspension (Extended Release)
    • Implant
    • Capsules (Delayed Release)
    • Powder for suspension
    • Ophthalmic Suspension
    • Tablet (Extended Release)
    • Vaginal Ring
    • Oral granule
    • Vaginal Suppository
    • Trans-dermal
    • Chewable Tablet
    • Tablet (Regular & Chewable)
    • Capsule (Soft-Gelatin/Liquid Fill)
    • Injectable Suspension [Otic]
    • Tablet (Extended Release, Orally Disintegrating)
    • Topical Suspension
    • Vaginal Insert (Extended Release)
    • For Intramuscular Suspension (Extended Release)
    • Tablet (Delayed Release)
    • Lozenges
    • Gel (Rectal)
    • For Oral Suspension (Delayed Release)
    • Capsule (Extended Release)
    • Injectable
    • Injectable (Liposomal)
    • Lozenge
    • Tablet, for suspension
    • Granule (Delayed Release)
    • Capsule (Liquid filled)
    • Buccal Tablet (Extended Release)
    • Suppository
    • For suspension (intravenous )
    • Tablet (Copackaged)
  • USP溶出方法
    • II (Paddle)
    • I (Basket)
    • II (Paddle)
    • II (Paddle)
    • VI (Cylinder)
    • II (Paddle)
    • II (Paddle) with wire sinker
    • II (Paddle)
    • II (Paddle)
    • Modified USP Type VI (cylinder)
    • I (Basket) (100 mesh)
    • Basket (20 mesh)
    • II (Paddle)
    • II (Paddle)
    • II (Paddle)
    • II (Paddle)
    • IV (Flow through cell)
    • Lumacaftor: II (Paddle); Ivacaftor: II (Paddle)
    • II (Paddle)
    • III (Reciprocating Cylinder [40 mesh (for bottom and top of the inner tube)]
    • II (Paddle)
    • I (Basket) 100 mL dissolution vessel
    • I (Basket)  100 mL round bottom vessel
    • II (Paddle)
    • Paddle over Disk (Apparatus 5)
    • VI (Cylinder) attach the patch to a disk at the bottom of the cylinder
    • I (Basket- 10 mesh)
    • II (Paddle)
    • II (Paddle)
    • II (Paddle)
    • II (Paddle) with sinker
    • II (Teflon coated paddle)
    • II (Paddle)
    • Reciprocating disk (Apparatus 7)
    • II (Paddle)
    • II (Paddle)
    • I (Basket-10 mesh)
    • I (Suppository, dissolution baskets, palmieri type)
    • IV (Flow through cell), 22.6 mm cell
    • V (Paddle over Disk) with a watchdish (a diameter of 6 cm)
    • II (Paddle) with PEAK vessels
    • II (Paddle)
    • II (Paddle)
    • II (Paddle)
    • II (Paddle)
    • II (Paddle) with sinker
    • II (Paddle)
    • II (Paddle) with option to use a sinker
    • I (Basket, with 20 mesh)
    • II (Paddle)
    • II (Paddle)
    • II (Paddle) with sinkers
    • II (Paddle)
    • Modified USP Type V (Paddle-over-disk)
    • II (Paddle)
    • II (Paddle)
    • II (Paddle)
    • II (Paddle)
    • II (Paddle)
    • II (Paddle)
    • II (Paddle)
    • II (Paddle) (diclo) II (Paddle) (miso)
    • Chewing Machine as desribed in European Pharmacopoeia (2.9.25)
    • II (Paddle)
    • I (Basket -100 mesh)
    • II (Paddle)
    • I (Basket) 100 mL dissolution vessel
    • Rotating Cylinder (Apparatus 6)
    • II (Paddle)
    • III (Reciprocating Cylinder) [Bottom Screen: 200 mesh stainless steel]
    • Reciprocating Cylinder (Apparatus 3 modified)
    • II (Paddle)
    • I (with Palmieri type basket)
    • I ( Basket)
    • V (Paddle over Disk) with 56 mm, 40 mesh stainless steel disk.
    • II (Paddle)
    • II (Paddle)
    • II (Paddle)
    • Niacin: I (40 mesh rotating Basket); Simvastain: I (10 mesh rotating Basket)
    • II (Paddle)
    • II (Paddle)
    • IV (Flow-Through Cell-Open system)
    • II (Paddle)
    • VII (Reciprocating holder)- cylinder.
    • Test 1: IV (Flow through cell), 22.6 mm cell, 13 g of 1 mm beads; Test 2: II (Paddle)
    • Prior to sampling, the jar is removed from incubation and mechanically swirled with digital orbital shaker
    • II (Paddle)
    • II (Paddle)
    • II (paddle)
    • II (Paddle)
    • II (Paddle)
    • V (Paddle over Disk) with a stainless steel disk (120 mesh screens)
    • I (Basket) for 75 strength: I (Basket with modified diameter of 24.5 mm) for 150 mg strength:
    • IV (Flow through cell-closed loop) / 22 mm
    • VI (Cylinder) attach the patch to the cylinder with double-sided tape
    • I (Basket- 20 mesh)
    • Dutasteride: II (Paddle) with sinker. Tamsulosin: II (Paddle)
    • II (Paddle)
    • II (Paddle)
    • II (Paddle)
    • II (Paddle)
    • II (Paddle), with option to use a sinker for 20/10 mg strength
    • II (Paddle)
    • III (Reciprocating Cylinder)
    • V (Paddle over disk). Paddle 25 mm above the film on the disk.
    • II (Paddle, may use sinker)
    • II (Paddle)
    • II (Paddle) A sinker may be used with justification if necessary.
    • Met: I (Basket, 40 mesh): Can: I (Basket, 10 mesh [with option of tablet holder])
    • II (Paddle) small volume dissolution apparatus
    • VII (with reciprocating 50 mesh baskets)
    • II (Paddle)
    • II (Paddle)
    • II (Paddle)
    • II (Paddle)
    • V (Paddle over Disk) with a stainless steel disk
    • II (Paddle)
    • Incubator shaker
    • II (Paddle)
    • II (Paddle
    • Cobi: II (Paddle): Drv: II (Paddle)
    • II (Paddle)
    • II (Paddle)
    • VII (Reciprocating holder) (Sample holder-Cage)
    • VI (Cylinder) with adapter, if needed
    • II (Paddle) with stainless steel stationary quadrangular hanging basket
    • II (Paddle)
    • II (Paddle)
  • 更新日期 -
  • 溶出介质
  • 转速
其他选项:
中国CDE注册与受理 NDA ANDA BLA 全选 上一页 下一页
首页 上一页 1 2 下一页 末页 GO
  • 药物名称
  • 剂型
  • USP溶出方法
  • 转速 (RPMs)
  • 溶出介质
  • 容积 (mL)
  • 推荐采样时间 (minutes)
  • 更新日期
  • Pirfenidone
  • Tablet
  • II (paddle)
  • 50
  • Water
  • 1000
  • 5, 10, 15, 20, 30 and 45
  • 2018-03-27
  • Doxycycline Hyclate ( 120 mg and 60 mg)
  • Tablet (Delayed Release)
  • I (Basket)
  • 100
  • Acid stage: 0.06 N HCl; Buffer stage: Neutralized Phthalate Buffer, pH 5.5
  • Acid stage: 900 mL; Buffer stage: 900 mL
  • Acid stage: 10, 20, 30, 45 and 60; Buffer stage: 5, 10, 15, 20, 30 and 45
  • 2018-03-27
  • Methscopolamine Bromide
  • Tablet
  • Refer to USP
  • 2018-02-15
  • Nitisinone
  • Tablet
  • II (paddle)
  • 50
  • Phosphate Buffer, pH 6.8
  • 2 mg tablets: 500 mL; 5 mg and 10 mg tablets: 900 mL
  • 10, 15, 20, 30, 45, 60, 75 and 90
  • 2018-02-15
  • Dexamethasone/Neomycin Sulfate/ Polymyxin B Sulfate
  • Ophthalmic Suspension
  • Develop a method to characterize in vitro release
  • 2018-02-15
  • Metyrosine
  • Capsule
  • Refer to USP
  • 2018-02-15
  • Ethinyl Estradiol/Norethindrone Acetate
  • Tablet
  • II (paddle)
  • 100
  • Phosphate Buffer, pH 6.8, containing 0.07% w/v Triton X 100
  • 900
  • 5, 10, 20, 30, 45, 60 and 75
  • 2018-02-15
  • Mecamylamine HCl
  • Tablet
  • Refer to USP
  • 2018-02-15
  • Triamcinolone Acetonide
  • II (paddle)
  • 75
  • 0.3% SDS in 10 mM phosphate buffer, pH 7.2 + 0.02% sodium azide @35°C
  • 1000
  • 1, 2, 4, 8, 12, 16, 24, 36, 48, 72, 96 and 120 hours
  • 2018-02-08
  • Omeprazole (Orally Disintegrating)
  • OTC Tablet (Delayed Release)
  • II (paddle)
  • 100
  • Tablets are pre-exposed to 500 ml of 0.1M HCL for 2 hrs and then 400 ml of 0.235M Na2HP04 is added to the medium. Adjust if necessary with 2 N HCI or 2 N NaOH to a pH of 6.8
  • Acid stage: 500; Buffer stage: 900
  • Acid stage: 120; Buffer stage: 10, 20, 30, 45 and 60
  • 2018-02-08
  • Acalabrutinib
  • Capsule
  • II (Paddle) with sinker
  • 50
  • 0.1 M HCl
  • 900
  • 5, 10, 15, 20, 30 and 45
  • 2018-02-08
  • Letermovir
  • Tablet
  • II (paddle)
  • 75
  • 25 mM Na Acetate Buffer, pH 4.5 with 0.6% Tween-80
  • 900
  • 10, 15, 20, 30, 45 and 60
  • 2018-02-08
  • Pregabalin
  • Tablet (Extended Release)
  • II (paddle)
  • 50
  • 0.06 M HCl
  • 900
  • 1, 2, 4, 6, 8, 10, 12, 16 and 24 hours
  • 2018-02-08
  • Medroxyprogesterone Acetate (104mg/0.65ml)
  • Injectable Suspension
  • Develop a method to characterize in vitro release
  • 2018-02-08
  • Aliskiren Hemifumarate
  • I (Basket)
  • 100
  • 0.01 M HCl (degas)
  • 500
  • 5, 10, 15, 20, 30 and 45
  • 2018-02-08
  • Dolutegravir Na/Rilpivirine HCl
  • Tablet
  • II (paddle)
  • 75
  • 1.0 % Tween 20 in 0.01 M HCl, pH 2.0
  • 900
  • 10, 15, 20, 30, 45 and 60
  • 2018-02-08
  • Triptorelin Pamoate
  • For Intramuscular Suspension (Extended Release)
  • II (paddle)
  • 75
  • 50 mL of methanol to 950 mL of water
  • 950
  • 1, 8, 24, 96, and 168 hours
  • 2017-11-16
  • Methylphenidate
  • II (paddle)
  • 75
  • Acid Stage: 0.1 N HCl; Buffer Stage: Phosphate Buffer, pH 6.8
  • Acid Stage: 900 mL; Buffer Stage: 1000 mL
  • Acid Stage: 15, 30, 60, 120 minutes; Buffer Stage: 1, 2, 3, 4, 6 and 8 hours
  • 2017-11-16
  • Betrixaban
  • Capsule
  • II (Paddle) with sinker
  • 75
  • 0.01 N HCl, (with addition of pepsin if gelatin crosslinking is observed)
  • 900
  • 5, 10, 15, 20 and 30
  • 2017-11-16
  • Ritonavir
  • I (Basket -100 mesh)
  • 100
  • 0.1 N HCl
  • 900
  • 5, 10, 15, 20 and 30
  • 2017-11-16